The strong efficacy and safety signals from this open-label pilot could drive near-term momentum, especially given the company's small market cap and prior positive clinical data. However, the open-label design and lack of a control group mean larger randomized trials are needed for FDA clearance. Watch for next steps in the HALO Clarity pivotal program and any FDA De Novo submission updates.
Price Chart
Executive Summary
Nexalin announced positive results from an open-label pilot trial of its DIFS 15mA/77.5Hz neurostimulation platform in adults with generalized anxiety disorder and comorbid insomnia. The trial showed rapid, large-magnitude improvements in anxiety (77.8% response rate, HAM-A -18.30 points) and depression (66.7% response/remission), with benefits maintained at 8-week follow-up and no serious adverse events. The company is preparing a product launch in Brazil and advancing its FDA De Novo regulatory pathway, but the open-label, single-center design limits the strength of the evidence.
Key Facts
- 77.8% anxiety response rate at end of treatment (Session 20).
- HAM-A scores decreased by 18.30 points by Session 20, maintained at 8-week follow-up.
- HAMD depression scores decreased by 9.90 points by Session 20; 66.7% response and remission rates.
- PSQI insomnia scores significantly improved at end of treatment and at 8-week follow-up with large effect sizes.
- No serious adverse events, seizures, or manic/hypomanic switches reported.
- Trial was single-center, open-label, prospective pilot at University of São Paulo (20 sessions over 4 weeks + 4-week follow-up).
- Nexalin is preparing a product launch and sales campaign in Brazil and advancing FDA De Novo submission.
- Company market cap ~$9M; pre-revenue clinical-stage neurostimulation developer.
Financial Impact
No financial data in filing; company is pre-revenue. Positive clinical data supports regulatory and commercial milestones but no revenue or deal value disclosed.
Risk Factors
- Open-label, single-center design limits generalizability and may overstate efficacy due to placebo effect.
- Company is pre-revenue with ~$9M market cap; capital needs for pivotal trials and commercialization are uncertain.
- FDA De Novo pathway is not yet submitted; regulatory approval timeline and requirements are unknown.
- Competition from established neurostimulation and pharmaceutical treatments for anxiety/depression.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309786 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | EFFECT | $2.35 | awaiting T+20 | — | $1.71 (+27.23%) |
Oct 8, 2026 18d ago | S-1/A | $3.63 | awaiting T+20 | — | $1.71 (+52.89%) |
Oct 1, 2026 25d ago | 8-K | $5.73 | awaiting T+20 | — | $1.71 (−70.16%) |
Oct 1, 2026 25d ago | 8-K | $5.73 | awaiting T+20 | — | $1.71 (−70.16%) |
Sep 2, 2026 7w ago | 8-K | $5.36 $4.28 | ▼ −20.15% | ▼ −19.03% | $1.71 (−68.10%) |
Aug 27, 2026 8w ago | 8-K | $0.2548 $0.1463 | ▼ −42.57% | ▼ −42.60% | $1.71 (+571.11%) |
Aug 17, 2026 10w ago | 8-K | $0.3400 $0.1617 | ▲ +52.45% | ▲ +50.47% | $1.71 (−402.94%) |
Jun 10, 2026 19w ago | Press Release | $0.4590 $0.4607 | ▲ +0.37% | ▼ −3.70% | $1.71 (+272.55%) |
May 19, 2026 22w ago | 8-K | $0.3350 $0.3680 | ▲ +9.85% | ▲ +9.11% | $1.71 (+410.45%) |
May 19, 2026 22w ago | Press Release | $0.3210 $0.3930 | ▲ +22.43% | ▲ +21.44% | $1.71 (+432.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers